Claims
- 1. A composition comprising viable cells of one or more tumor cell lines, which cell line or lines provide to a composition an antigenically effective amount of each of GD2 ganglioside, GM2 ganglioside, M-TAA, and either M-fetal antigen or M-urinary antigen, the antigens being included in the composition in amounts effective to elicit an antibody response against said antigens, the composition being suitable for injection to an animal and said one or more tumor cell lines rendered incapable of proliferation in vivo.
- 2. The composition of claim 1, wherein the cell line or lines provide to the composition an antigenically effective amount of GD2 ganglioside, GM2 ganglioside, M-TAA, M-fetal antigen and M-urinary antigen.
- 3. A pharmaceutically acceptable composition comprising one or more cell lines selected from the group consisting of cell line M10(ATCC CRL-12269), M24(ATCC CRL-12270), and M101(ATCC CRL-12271), the composition comprising a pharmaceutically acceptable excipient or diluent, wherein said one or more cell lines are rendered incapable of proliferation in vivo.
- 4. The composition of claim 3, wherein the selected cell line is M10(ATCC CRL-12269).
- 5. The composition of claim 3, wherein the selected cell line is M24(ATCC CRL-12270).
- 6. The composition of claim 3, wherein the selected cell line is M10(ATCC CRL-12271).
- 7. The composition of claim 3, wherein the composition includes all three cell lines.
- 8. The composition of claim 3, wherein the one or more cell lines have been rendered incapable of proliferation bv irradiation.
Parent Case Info
The present application is a division of U.S. Ser. No. 07/961,786, filed Oct. 14, 1992, which is a continuation-in-part of U.S. Ser. No. 07/908,638, filed Jul. 2, 1992, now abandoned, which is a continuation of U.S. Ser. No. 07/510,602, filed Apr. 18, 1990, now abandoned; also U.S. Ser. No. 07/961,786, filed Oct. 14, 1992, is a continuation-in-part of U.S. Ser. No. 07/431,533, filed Nov. 3, 1989.
Government Interests
The U.S. Government has rights in the present invention pursuant to grants CA 12582 and CA 29605 from the National Cancer Institute.
US Referenced Citations (6)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0 668 350 A1 |
Aug 1995 |
EPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
961786 |
Oct 1992 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
510602 |
Apr 1990 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
908638 |
Jul 1992 |
|
Parent |
431533 |
Nov 1989 |
|